RLMD Stock Forecast: Relmada Therapeutics, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$2.61
−16.08% on the day

The median 12-month analyst price target for Relmada Therapeutics, Inc. is $11. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 55 of 100 as at 21 Nov 2026 — in the upper half.

Market cap
$279.5M
Ticker Nerd rank
55/ 100
Median analyst target
$11
Analysts covering
4
Revenue$0.0
Operating income−$15.0M
Net income−$12.9M
Free cash flow−$9.6M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−38.0%
1M
−22.3%
YTD
−46.0%
1Y
−39.6%
From 52W high
−66.8%
From 52W low
0.0%
$2.61
$7.86
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Relmada Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
55/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
77
Momentum
73
Quality
67
Value
54
Growth
38
Accruals
35
Issuance
25
Volatility
24

Revisions (77): Analysts have, on balance, been raising their forecasts.

Volatility (24): The share price moves around a lot.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

RLMD stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on RLMD, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$4.00$6.00$8.00$10.00$12.00Jan 26Apr 26Jul 26Oct 26RLMDHigh $12Median $11Low $9

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says4 analysts
4
Buy
0
Hold
0
Sell
$9
Low
$11
Median
$12
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 June 2026HC Wainwright & Co.InitiatesBuy$12
24 Mar 2026Piper SandlerInitiatesOverweight—
20 Mar 2026MizuhoMaintainsOutperform—
2 Mar 2026LUCID CAPITAL MARKETSInitiatesBuy—
23 Jan 2026Leerink PartnersUpgradeOutperform—
22 Dec 2025JefferiesInitiatesBuy—
19 Nov 2025MizuhoUpgradeOutperform—
5 Dec 2024MizuhoDowngradeNeutral—
4 Dec 2024Leerink PartnersDowngradeMarket Perform—
17 Sept 2024JefferiesUpgradeBuy$3.50 → $13
5 June 2024Goldman SachsDowngradeSell—
15 June 2023MizuhoReiteratesBuy—
23 Jan 2023SVB LeerinkMaintainsOutperform—
14 Oct 2022Goldman SachsDowngradeNeutral—
14 Oct 2022GuggenheimDowngradeNeutral—
13 Oct 2022OppenheimerDowngradePerform—
23 Sept 2022Goldman SachsMaintainsBuy—
6 Sept 2022GuggenheimMaintainsBuy—
9 May 2022OppenheimerMaintainsOutperform—
24 Mar 2022Goldman SachsMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for RLMD.

Market Radar

This page is one stock. Monday covers all of them.

RLMD appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

RLMD vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Relmada Therapeutics, Inc. returned −39.6% against +6.9% for the S&P 500, dividends included.

RLMD vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140160180Jan 26Apr 26Jul 26Oct 26RLMDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

RLMD analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
1
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
1.4×

Cheaper than 56% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−64.7%

Higher than 18% of US stocks

Return on assets
−36.9%

Higher than 12% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Relmada Therapeutics, Inc. has a market value of $279.5M and an enterprise value of $77.4M.

  • Revenue in the twelve months to 30 June 2026: $0.0.

  • Net income over the same four quarters: −$61.9M.

  • Free cash flow in the twelve months to 30 June 2026: −$46.0M.

  • Shares outstanding: 106.7M.

  • Relmada Therapeutics, Inc. employs 17 people.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 22 Nov 2026

Data provided by Twelve Data

Peers

RLMD and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
RLMDRelmada Therapeutics, Inc.$279.5M55
GALTGalectin Therapeutics, Inc.$271.3M82
NAUTNautilus Biotechnology, Inc.$269.4M70
FULCFulcrum Therapeutics, Inc.$281.5M35
GLSIGreenwich LifeSciences, Inc.$282.6M53
AGENAgenus, Inc.$267.2M82
BNTCBenitec Biopharma, Inc.$285.9M39

Take a look at RLMD’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Relmada Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about RLMD

What is the RLMD stock price forecast for 2026-2027?

The median 12-month analyst price target for Relmada Therapeutics, Inc. is $11, with estimates ranging from $9 to $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is RLMD stock a buy right now?

Of the 4 analysts covering Relmada Therapeutics, Inc., 4 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Relmada Therapeutics, Inc. 55 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank RLMD?

As at 21 Nov 2026, Relmada Therapeutics, Inc. ranks 55 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (77 of 100).

Will RLMD stock go up?

No one can know that. What the data says: the median 12-month target from 4 analysts is $11, and Ticker Nerd's factor model ranks Relmada Therapeutics, Inc. 55 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the RLMD stock forecast for 2030?

No analyst covering Relmada Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for RLMD are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $9 to $12 over the next 12 months.

How has RLMD stock performed over the past year?

Relmada Therapeutics, Inc. returned -39.6% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Relmada Therapeutics, Inc. do?

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions.

Company

About Relmada Therapeutics, Inc.

Relmada Therapeutics Inc. is a clinical-stage biotechnology company focused on developing therapies for oncology and central nervous system disorders. Its current pipeline centers on product candidates designed to address areas of significant unmet medical need, including NDV-01 for non-muscle invasive bladder cancer and sepranolone for neurological and compulsivity-related conditions. The company also advances esmethadone, a novel NMDA receptor antagonist being evaluated for central nervous system indications such as major depressive disorder and other related disorders. Relmada Therapeutics Inc. operates as a research-driven drug developer, using targeted clinical programs to explore new treatment options across cancer, psychiatric, and neurological care. Headquartered in Coral Gables, Florida, the company remains focused on late-stage development of proprietary therapies intended to expand treatment possibilities in specialized disease areas.

CEO Dr. Sergio Traversa M.B.A., Pharm.D. · 17 employees · United States · https://www.relmada.com